Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

Share Price is delayed by 15 minutes
Get Live Data
113.00    1.50 (1.35%)
Bid:
112.00
Ask:
114.00
Spread: 2.00 (1.786%)
Market Cap: £67.98m
IGP Live PriceLast checked at - London Stock Exchange

Intraday Intercede Share Chart

Trading Update

24 Jul 2008 07:00

RNS Number : 7526Z
Intercede Group PLC
24 July 2008
 



24 JULY 2008

INTERCEDE GROUP PLC

("Intercede" or "the Company")

Trading Update 

Intercede, a leading producer of Identity and Credential Management Systems (IDCMS) software, today announces that in the first three months of the current financial year it has made strong commercial progress compared to the previous year.

Software deliveries to previously announced major customers in the UK, Europe and the US have been completed on time and ongoing development work is proceeding according to contractual schedules. The trading performance for the quarter ending 30 June 2008 reflects this continued progress resulting in increased revenues and reduced losses year on year. 

Further progress has also been made with the selection of Intercede's MyID technology for the following projects:

 

·; Two additional US Federal Agencies (bringing the total number served by Intercede‘s technology to 10) will be using MyID to issue secure credentials.
·; A MyID system has been installed to power a First Responder (FRAC) service in a large US state.
·; A managed service incorporating MyID has been deployed by an Intercede partner to support a large US Military Base.
·; Intercede’s first Australian MyID customer.
·; An additional UK Government contract.

 

Richard Parris, Chairman and Chief Executive of Intercede, commented:

"The level of activity in all aspects and regions of our business is greater than it has ever been and we are benefiting from participating in one of the few technology markets that is rapidly growing in spite of the general economic downturn. The overall prospects for the Group remain positive and I expect Intercede to deliver enhanced financial performance in the current financial year and beyond".

About Intercede

Intercede Group plc is a leading developer and supplier of smart card and identity management software listed on the London Stock Exchange (IGP LN) (IGP.L). Intercede's MyID software manages the secure registration, issuance and lifecycle of digital identities for a wide range of uses. This requires the integration of multiple technologies and products from many different vendors, including smart cards, biometrics, digital certificates, Open Platform applets and physical access control systems.

Intercede works with a number of market leading OEM, re-seller and technology partners that supply MyID technology to the global market place including: Athena Smartcard Solutions, Gemalto, Oberthur Card Systems, Oracle, RSA Security, SafeNet, Thales, VeriSign and a variety of systems integrators and other security product and service providers. 

Intercede and MyID are registered trademarks or trademarks in the UK, US and/or other countries. For more information visit http://www.intercede.com

ENQUIRIES

Intercede Group plc

Tel. +44 (0)1455 558111

Richard Parris, Chairman & Chief Executive

Andrew Walker, Finance Director

KBC Peel Hunt

Tel. +44 (0)20 7418 8900

Richard Kauffer

Daniel Harris

Pelham Public Relations

Archie Berens

Tel. +44 (0)20 7743 6679

Robert Koh

Tel. +44 (0)20 3170 7444

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSELFMDSASEDW
Date   Source Headline
24th Oct 20237:00 amRNSNotice of Interim Results & Investor Presentation
20th Oct 20237:03 amRNSAppointment of Non-Executive Director
11th Oct 20237:00 amRNSDirector/PDMR Shareholding
10th Oct 20237:00 amRNSTrading Update
21st Sep 20231:31 pmRNSResult of AGM
4th Sep 20237:00 amRNSContract and Renewals Orders
30th Aug 20237:10 amRNSNotice of AGM and Publication of Annual Report
20th Jun 20237:01 amRNSBoard Changes
20th Jun 20237:00 amRNSFinal Results
12th Jun 20237:00 amRNSNotice of Results & Investor Presentation
27th Apr 20237:00 amRNSShare Incentive Plan
17th Apr 20237:00 amRNSTrading Update
3rd Apr 20237:00 amRNSContract wins/renewals
3rd Feb 202310:46 amRNSDirector/PDMR Shareholding
31st Jan 20237:00 amRNSChange of Auditors
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
23rd Jan 20232:00 pmRNSPrice Monitoring Extension
23rd Jan 20237:00 amRNSTrading Update
11th Jan 20232:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20228:45 amRNSDirector/PDMR Shareholding
22nd Nov 20227:00 amRNSHalf-year Report
11th Nov 20227:00 amRNSNotice of Interim Results & Investor Presentation
13th Oct 202210:30 amRNSDirector/PDMR Shareholding
11th Oct 20221:00 pmRNSDirector/PDMR Shareholding
10th Oct 20228:00 amRNSLong Term Incentive Plan
10th Oct 20227:01 amRNSAcquisition of Authlogics Ltd
10th Oct 20227:00 amRNSTrading Update
28th Sep 202212:22 pmRNSResult of AGM
15th Sep 20227:00 amRNSDirector/PDMR Shareholding and Issue of Equity
10th Aug 20227:00 amRNSNotice of AGM
30th Jun 20227:00 amRNSBoard Changes
8th Jun 20227:00 amRNSFinal Results
25th May 202210:15 amRNSInvestor Presentation
12th Apr 20227:00 amRNSAppointment of CFO
6th Apr 20227:00 amRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSTrading Update & Contract Win
30th Mar 202210:01 amRNSReceipt of $3.4m Order
2nd Feb 20227:00 amRNSContract Win
8th Dec 20213:55 pmRNSDirector/PDMR Shareholding and Issue of Equity
23rd Nov 20217:00 amRNSHalf-year Report
19th Nov 20217:00 amRNSHolding(s) in Company-Amendment
17th Nov 20217:00 amRNSInvestor Presentation
16th Nov 20217:00 amRNSHolding(s) in Company
15th Nov 20213:45 pmRNSTotal Voting Rights
11th Nov 20214:12 pmRNSHolding(s) in Company
11th Oct 20217:00 amRNSTrading Update
15th Sep 20212:09 pmRNSResult of AGM
15th Sep 20217:00 amRNSMultiple Customers choose to Upgrade MyID

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.